Even though IHC-assessed MET overexpression may be utilized as a surrogate marker to screen for MET amplification, clinical studies have not entirely clarified the concordance between MET overexpression and MET mutation/amplification as predictive biomarkers and indicators of NSCLC dependence on MET signaling [57,58,60,64,65]. Here, MET is linked to non-small cell lung carcinoma.